Dr. Rachel Koldej
Honorary
Medicine - Royal Melbourne Hospital
56 Scholarly works
1 Projects
HIGHLIGHTS
2021
Journal article
Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence
DOI: 10.1186/s12967-021-03136-22021
Journal article
Venetoclax or Ruxolitinib in Pre-Transplant Conditioning Lowers the Engraftment Barrier by Different Mechanisms in Allogeneic Stem Cell Transplant Recipients
DOI: 10.3389/fimmu.2021.7490942021
Journal article
Dissection of the bone marrow microenvironment in hairy cell leukaemia identifies prognostic tumour and immune related biomarkers
DOI: 10.1038/s41598-021-98536-12021
Journal article
Clinical features, pathophysiology and therapy of Poor Graft Function Post Allogeneic Stem Cell Transplantation.
DOI: 10.1182/bloodadvances.20210045372021
Conference Proceedings
Abstract CT208: Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study
DOI: 10.1158/1538-7445.am2021-ct2082021
Conference Proceedings
Phase I Dose Escalation Study of Radiotherapy and Durvalumab (MEDI4736) in Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL): The RaDD Study.
2015
Research Grant
Circulating microRNA as a biomarker in brain cancer
RECENT SCHOLARLY WORKS
2021
Conference Proceedings
IMMUNE PRIMING WITH NIVOLUMAB FOLLOWED BY NIVOLUMAB & RITUXIMAB IN 1 ST LINE TREATMENT OF FOLLICULAR LYMPHOMA: THE PHASE 2 1 ST FLOR STUDY
DOI: 10.1002/hon.81_28792021
Journal article
T cell receptor beta locus sequencing early post-allogeneic stem cell transplant identifies patients at risk of initial and recurrent cytomegalovirus infection
DOI: 10.1038/s41409-021-01354-22021
Conference Proceedings
Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.
DOI: 10.1200/JCO.2021.39.15_suppl.75602021
Journal article
Volatile anaesthesia and peri-operative outcomes related to cancer: a feasibility and pilot study for a large randomised control trial
DOI: 10.1111/anae.15354